|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMEM203 |
Gene summary for TMEM203 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMEM203 | Gene ID | 94107 |
| Gene name | transmembrane protein 203 | |
| Gene Alias | HBEBP1 | |
| Cytomap | 9q34.3 | |
| Gene Type | protein-coding | GO ID | GO:0000003 | UniProtAcc | Q969S6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 94107 | TMEM203 | P76T-E | Human | Esophagus | ESCC | 1.87e-05 | 1.87e-01 | 0.1207 |
| 94107 | TMEM203 | P79T-E | Human | Esophagus | ESCC | 3.73e-04 | 1.25e-01 | 0.1154 |
| 94107 | TMEM203 | P80T-E | Human | Esophagus | ESCC | 1.70e-07 | 3.12e-01 | 0.155 |
| 94107 | TMEM203 | P82T-E | Human | Esophagus | ESCC | 1.61e-04 | 2.61e-01 | 0.1072 |
| 94107 | TMEM203 | P83T-E | Human | Esophagus | ESCC | 4.93e-15 | 4.38e-01 | 0.1738 |
| 94107 | TMEM203 | P89T-E | Human | Esophagus | ESCC | 1.83e-04 | 2.28e-01 | 0.1752 |
| 94107 | TMEM203 | P91T-E | Human | Esophagus | ESCC | 2.30e-12 | 9.80e-01 | 0.1828 |
| 94107 | TMEM203 | P107T-E | Human | Esophagus | ESCC | 2.03e-16 | 3.95e-01 | 0.171 |
| 94107 | TMEM203 | P126T-E | Human | Esophagus | ESCC | 1.05e-08 | 7.09e-01 | 0.1125 |
| 94107 | TMEM203 | P127T-E | Human | Esophagus | ESCC | 5.13e-06 | 1.79e-01 | 0.0826 |
| 94107 | TMEM203 | P128T-E | Human | Esophagus | ESCC | 1.05e-19 | 5.30e-01 | 0.1241 |
| 94107 | TMEM203 | P130T-E | Human | Esophagus | ESCC | 1.17e-21 | 4.40e-01 | 0.1676 |
| 94107 | TMEM203 | HCC1_Meng | Human | Liver | HCC | 4.88e-47 | 8.35e-02 | 0.0246 |
| 94107 | TMEM203 | HCC2_Meng | Human | Liver | HCC | 1.11e-18 | 1.03e-01 | 0.0107 |
| 94107 | TMEM203 | cirrhotic2 | Human | Liver | Cirrhotic | 3.45e-03 | 1.53e-01 | 0.0201 |
| 94107 | TMEM203 | cirrhotic3 | Human | Liver | Cirrhotic | 8.50e-06 | 1.38e-01 | 0.0215 |
| 94107 | TMEM203 | HCC1 | Human | Liver | HCC | 7.81e-08 | 3.79e+00 | 0.5336 |
| 94107 | TMEM203 | HCC2 | Human | Liver | HCC | 1.98e-07 | 3.65e+00 | 0.5341 |
| 94107 | TMEM203 | Pt13.b | Human | Liver | HCC | 2.62e-09 | 1.26e-01 | 0.0251 |
| 94107 | TMEM203 | Pt14.b | Human | Liver | HCC | 3.28e-02 | 1.68e-01 | 0.018 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMEM203 | SNV | Missense_Mutation | novel | c.309G>C | p.Gln103His | p.Q103H | Q969S6 | protein_coding | deleterious(0.05) | possibly_damaging(0.85) | TCGA-AJ-A2QM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Chemotherapy | carboplatin | CR |
| TMEM203 | SNV | Missense_Mutation | c.370N>G | p.Leu124Val | p.L124V | Q969S6 | protein_coding | tolerated(0.07) | benign(0.217) | TCGA-49-AARE-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| TMEM203 | SNV | Missense_Mutation | c.138N>T | p.Trp46Cys | p.W46C | Q969S6 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-BR-4257-01 | Stomach | stomach adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| TMEM203 | SNV | Missense_Mutation | c.172N>A | p.Gly58Arg | p.G58R | Q969S6 | protein_coding | tolerated(0.11) | probably_damaging(0.996) | TCGA-HU-A4GQ-01 | Stomach | stomach adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
| TMEM203 | SNV | Missense_Mutation | novel | c.113A>G | p.Asp38Gly | p.D38G | Q969S6 | protein_coding | deleterious(0.02) | probably_damaging(0.922) | TCGA-DJ-A3VK-01 | Thyroid | thyroid carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |